


Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver...


Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label,


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19-21; Washington DC. 2014.;


Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-1086.


Maurer K, Gondles EF, Efeti D, Strom HV, Strom HV. Hepatitis C in correctional settings: challenges and opportunities. 2015;


Morey S, Hamoodi A, Jones D, Young T. Increased diagnosis and treatment of hepatitis C in prison by universal offer of

Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic

Morgan RL, Baack B, Smith BD, Yartel A, Pitsam, Falck-Ytter Y. Eradication of hepatitis C virus infection and the
1):329-337.


Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen

Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to


Moyer VA. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation

Mücke MM, Backus LI, Mücke VT. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a

Murphy SM, Dweik D, McPherson S, Roll JM. Association between hepatitis C virus and opioid use while in

Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty

Myers JJ, Shade SB, Rose CDawson, Koester K, Maiorana A, Malitz FE, et al. Interventions Delivered in Clinical Settings
are Effective in Reducing Risk of HIV Transmission Among People Living with HIV: Results from the Health Resources
and Services Administration (HRSA)‘s Special Projects of National Significance Initiative. AIDS and Behavior.

Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and
overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol.
2019;54(8):752-761.


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR.


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;.


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.


Information sheet on naltrexone therapy [Internet]. Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


Zuckerman E, Ashkenasi E, Kovalev Y, et al. The real world Israeli experience of treating chronic hepatitis C genotype 1 patients with advanced fibrosis with parataprevir/ ritonavir/ ombitasvir, dasabuvir with or without ribavirin: a large, multi-